GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
- Conditions
- Neoplasms, Uterine CervixMetastatic Cervical Cancer
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 228
- Registration Number
- NCT00430781
- Locations
- 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
- Conditions
- InfluenzaInfluenza Vaccines
- Interventions
- Biological: Pandemic influenza vaccine (GSK1119711A)-formulation 1Biological: Pandemic influenza vaccine (GSK1119711A)-formulation 2
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 512
- Registration Number
- NCT00430521
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00429728
- Locations
- 🇺🇸
GSK Investigational Site, Willingboro, New Jersey, United States
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
- Conditions
- Rhinitis, Allergic, SeasonalSeasonal Allergic Rhinitis
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00430157
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- Biological: trastuzumabDrug: epidoxorubicin
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00429299
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants
- Conditions
- Hepatitis B
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2464
- Registration Number
- NCT00429481
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
- Conditions
- Overactive Bladder
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00427596
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 862
- Registration Number
- NCT00428090
- Locations
- 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Mencevax™ ACWYBiological: GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)Biological: Meningitec™
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 613
- Registration Number
- NCT00427908
- Locations
- 🇫🇮
GSK Investigational Site, Vantaa, Finland
A Three-Part Study Of GSK580416 In Healthy Subjects
- Conditions
- Respiratory Tract InfectionInfections, Bacterial
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00427141
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia